ETFs Gilead Sciences, Inc.

GILD

US3755581036

Name	Weight	AuM	1st Jan change
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	13.99%	378 M€	-9.62%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.55%	1 M€	0.00%	-
FRANKLIN U.S. LOW VOLATILITY HIGH DIVIDEND INDEX ETF - USD	2.9%	507 M€	+5.54%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	2.66%	21 M€	+4.29%	-
VANECK MORNINGSTAR US SUSTAINABLE WIDE MOAT UCITS ETF - USD	2.62%	323 M€	+0.07%	-
FIRST TRUST MORNINGSTAR DIVIDEND LEADERS ETF (CAD-HEDGED) - CAD	2.58%	6 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	2.27%	3 M€	-.--%	-
OSSIAM WORLD ESG MACHINE LEARNING UCITS ETF 1A - EUR	1.96%	0 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.26%	6 M€	0.00%	-
AMUNDI INDEX MSCI USA SRI PAB - UCITS ETF DR (C) - EUR	1.23%	0 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS MINIMUM VOLATILITY BLUE UCITS ETF B - USD	1.21%	0 M€	-.--%	-
HARTFORD DISCIPLINED US EQUITY ETF - USD	1.16%	131 M€	+6.69%	-
VICTORYSHARES US EQ INCOME ENHANCED VOLATILITY WTD ETF - USD	1.04%	643 M€	+3.47%	-
DIREXION NASDAQ-100 EQUAL WEIGHTED ETF - USD	1.01%	1,034 M€	+10.39%	-
LEVERAGE SHARES -5X SHORT NASDAQ 100 ETP - USD	0.98%	5 M€	-66.91%	-
LEVERAGE SHARES PUBLIC LIMITED COMPANY - 3X LONG US TECH 100 ETP	0.98%	2 M€	-.--%	-
HARTFORD LONGEVITY ECONOMY ETF - USD	0.92%	13 M€	+2.26%	-

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

08-04 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

AAA

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

109.85USD

Average target price

116.85USD

Spread / Average Target

+6.37%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 19:57:55 17/07/2025 BST			5-day change	1st Jan Change
109.02 ^USD	-0.76%		-4.88%	+17.94%

07-16	Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing	MT
07-16	Gilead Sciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 11:20 AM